Figure 1. Antitumor immune effects of novel universal CD4 helper peptides derived from telomerase (UCP). UCP-based antitumor vaccines favor DC activation which provides costimulatory signals to antitumor CTL, enhancing their quantity, quality and recruitment at the tumor site. Concomittantly chemotherapy can act by promoting immunogenic cell death and antitumor T cell activation.